Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Core Points - Clearmind Medicine Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, as confirmed by a notification letter from Nasdaq on December 10, 2025 [1][2] - The company is under continued monitoring by Nasdaq for compliance with the Minimum Stockholders' Equity Rule, with potential delisting if compliance is not demonstrated in the next periodic report [2] - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [3] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [4]